Company Filing History:
Years Active: 2011-2024
Title: Zunhong Ke: Innovator in Gene Therapy and Angiogenic Eye Disorder Treatments
Introduction
Zunhong Ke is a prominent inventor based in Chengdu, China. He has made significant contributions to the fields of gene therapy and ophthalmology. With a total of 2 patents, his work focuses on innovative methods for treating complex medical conditions.
Latest Patents
Zunhong Ke's latest patents include groundbreaking methods for treating angiogenic eye disorders using VEGF antagonists. This patent application provides methods for treating patients with angiogenic eye disorders by administering a VEGF antagonist, particularly one that comprises the amino acid sequence of SEQ ID NO:1 in one or more treatment phases. Another notable patent involves the construction of an oncolytic adenovirus recombinant that specifically expresses the immune modulatory factor GM-CSF in tumor cells. This invention relates to gene therapy for tumors and outlines the uses of this innovative approach.
Career Highlights
Throughout his career, Zunhong Ke has worked with notable companies such as Chengdu Kanghong Biotechnologies Co., Ltd. and Chengdu Kanghong Pharmaceutical Co., Ltd. His expertise in biotechnology and pharmaceuticals has positioned him as a key player in the development of therapeutic solutions.
Collaborations
Zunhong Ke has collaborated with esteemed colleagues, including Yongguo Yu and Yiqian Wang. These partnerships have further enhanced his research and development efforts in the medical field.
Conclusion
Zunhong Ke's contributions to gene therapy and treatments for angiogenic eye disorders highlight his innovative spirit and dedication to improving patient outcomes. His work continues to influence the medical community and pave the way for future advancements.